Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Immunogenicity of Inactivated Influenza Virus Vaccine Among Healthy Children 6-12 Weeks of Age (GRC28)

This study has been completed.
Sponsor:
Collaborator:
Sanofi Pasteur, a Sanofi Company
Information provided by:
Seattle Children's Hospital
ClinicalTrials.gov Identifier:
NCT00242424
First received: October 19, 2005
Last updated: January 27, 2009
Last verified: January 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2007
  Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Publications:
Englund JA, Walter EB, Black S, et al. Safety and Immunogenicity of Fluzone Trivalent Inactivated Influenza Vaccine (TIV) in Infants 6-12 Weeks of Age. Presented at Infectious Disease Society of America (IDSA), Toronto, Oct. 14, 2006